AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11376277
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of SH U 508A (1 mL/min)
Trial: 11376277
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of SH U 508A
Trial: 11376277
Drug: Individualized infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized infusion of SH U 508A
Trial: 8433354
Drug: Detection behaviors
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection behaviors (e.g., cholesterol check)
Trial: 8433354
Drug: Promotion behaviors
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Promotion behaviors (e.g., eating a low-fat diet)
Trial: 29843755
Drug: G +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + MK (gemcitabine + MK-0646)
Trial: 29843755
Drug: G +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + MK + E (gemcitabine + MK-0646 + erlotinib)
Trial: 29843755
Drug: G +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + E (gemcitabine + erlotinib)
Trial: 25592781
Drug: IFN and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN and low doses of MTX
Trial: 23418958
Drug: Standard cardiovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cardiovascular treatment according to Dutch guidelines
Trial: 22029856
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 mcg
Trial: 16995545
Drug: Customized aspheric
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized aspheric treatment zone (CATz)
Trial: 14722370
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation (60 mg)
Trial: 14722370
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly iron supplementation (60 mg)
Trial: 9163024
Drug: Antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral treatment with aciclovir
Trial: 1351888
Drug: nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebivolol 5 mg once daily for 4 weeks
Trial: 6584561
Drug: Carminomycin (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carminomycin (18 mg/m2)
Trial: 6584561
Drug: 4'-epidoxorubicin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4'-epidoxorubicin (90 mg/m2)
Trial: 30391573
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy with 45 Gy/30 twice-daily fractions over 19 days
Trial: 30391573
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy with 66 Gy/33 once-daily fractions over 45 days
Trial: 30391573
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (both groups)
Trial: 25654629
Drug: Individualized program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized program including exercise therapy plus risk factor modification for 12 weeks
Trial: 20880729
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg plus placebo
Trial: 15235556
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine combined with sufentanil at a dose of 0.5 microg/ml(‐1) (group A)
Trial: 15235556
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine combined with sufentanil at a dose of 0.75 microg/ml(‐1) (group B)
Trial: 15235556
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine combined with sufentanil at a dose of 1 microg/ml(‐1) (group C)
Trial: 2169378
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose concentration maintained at 4.5 mmol/l (euglycaemia)
Trial: 2169378
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose concentration maintained at 3.5 mmol/l (mild hypoglycaemia)
Trial: 224997
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (cyclophosphamide, doxorubicin, and imidazole carboximide)
Trial: 224997
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with cycle-active therapy (vincristine, hydroxyurea, and methotrexate)
Trial: 6660827
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution, 10 ml per 1000 g of patient weight injected into the peritoneal cavity before closing the incision.
Trial: 6660827
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no saline solution injection).
Trial: 29398576
Drug: Real tVNS
RxNorm normalized name: TVN-102
DrugBank: TVN-102 (DB16990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real tVNS treatment
Trial: 29398576
Drug: Sham tVNS
RxNorm normalized name: TVN-102
DrugBank: TVN-102 (DB16990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tVNS treatment
Trial: 25152605
Drug: NSAID-muscovite group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID-muscovite group (3 g of muscovite + 75 mg slow-release diclofenac, twice daily for 14 d)
Trial: 25152605
Drug: NSAID control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID control group (75 mg slow-release diclofenac, twice daily for 14 d)
Trial: 20016013
Drug: Corrected fractional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corrected fractional iron absorption in children
Trial: 15630172
Drug: Liposomal lactoferrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal lactoferrin, 319 mg per day for four weeks
Trial: 11789395
Drug: Perindopril +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril + indapamide treatment
Trial: 9435041
Drug: Imipenem/cilastatin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (1.5 g/day)
Trial: 9435041
Drug: Meropenem (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (3.0 g/day)
Trial: 2442551
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg (increased to 80 mg if necessary)
Trial: 2442551
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg (increased to 200 mg if necessary)
Trial: 2442551
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 12.5 or 25 mg added after 12 weeks if necessary
Trial: 24619576
Drug: 10% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% lidocaine sprayed on the laryngoscope blade (group L)
Trial: 20618964
Drug: Chicory root
RxNorm normalized name: Chicory Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicory root extract (600 mg/day, 1200 mg/day, 1800 mg/day for 1 month)
Trial: 16259626
Drug: Resource-oriented music
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resource-oriented music therapy (biweekly sessions for three months)
Trial: 9532410
Drug: Interleukin-2-based therapy
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-2-based therapy (same as originally used)
Trial: 9532410
Drug: Different interleukin-2-based
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different interleukin-2-based therapy (including tumor-infiltrating lymphocytes)
Trial: 9532410
Drug: Interleukin-2-based therapy
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-2-based therapy (initial response)
Trial: 9532410
Drug: Interleukin-2-based therapy
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-2-based therapy (partial response)
Trial: 9532410
Drug: Interleukin-2-based therapy
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-2-based therapy (complete response)
Trial: 7498222
Drug: 99mTc‐L,L‐EC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐L,L‐EC
Trial: 25125271
Drug: Self-administered HIV/HCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered HIV/HCV risk assessment plus brief intervention about drug misuse and screening for HIV/HCV
Trial: 25125271
Drug: Self-administered HIV/HCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered HIV/HCV risk assessment alone (control)
Trial: 17564103
Drug: Propiverine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine alone (monotherapy group, n = 52)
Trial: 17564103
Drug: Propiverine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine plus urapidil (combination group, n = 48)
Trial: 11466989
Drug: Physical training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical training programme (twice a week for three months)
Trial: 9465812
Drug: Preoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative administration of two injections of leuprolide acetate 28 days apart (group A)
Trial: 7486614
Drug: CNS 1102
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CNS 1102 (aptiganel hydrochloride) administered in doses of up to 100 micrograms/kg
Trial: 7486614
Drug: CNS 1102
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CNS 1102 administered as a 15-minute intravenous infusion, a 15-minute loading intravenous infusion followed by a 4-hour maintenance infusion, or as a fixed-dose intravenous bolus over 90 seconds
Trial: 2650735
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g margarine added to soup
Trial: 2650735
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g margarine added to mashed potato
Trial: 964056
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment with neomycin and bacitracin for 4 days preoperatively
Trial: 964056
Drug: Mechanical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical and dietary preparation only (Control)
Trial: 964056
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment with neomycin and bacitracin
Trial: 31059146
Drug: Hydrocortisone (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (lower dose) in secondary adrenal insufficiency
Trial: 31059146
Drug: Hydrocortisone (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (higher dose) in secondary adrenal insufficiency
Trial: 31059146
Drug: Stable hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Stable hydrocortisone and fludrocortisone therapy in primary adrenal insufficiency
Trial: 28596150
Drug: Pregabalin (PGB)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin (PGB) + Alpha-lipoic acid (ALA) combination
Trial: 24651301
Drug: AryoSeven (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AryoSeven (30 μg/kg, intravenously per week for 4 weeks)
Trial: 24651301
Drug: NovoSeven (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovoSeven (30 μg/kg, intravenously per week for 4 weeks)
Trial: 22364530
Drug: Amine fluoride
RxNorm normalized name: triethylene amine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride toothpaste and gel (Elmex(®))
Trial: 22364530
Drug: 0.12% spray-chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% spray-chlorhexidine (Perio-Aid(®))
Trial: 19667268
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with paclitaxel (AC followed by paclitaxel)
Trial: 19667268
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy without paclitaxel (AC only)
Trial: 15025551
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost 2.5 or 5 microg six or nine times daily for 12 weeks
Trial: 10806696
Drug: Nimodipine 30
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg orally
Trial: 10806696
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (control)
Trial: 1996187
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release diltiazem (maximum dose 360 mg daily)
Trial: 1996187
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release diltiazem (minimum dose 120 mg)
Trial: 1996187
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release diltiazem (up to 360 mg daily)
Trial: 23307827
Drug: Oral treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral treprostinil (0.25 mg tablets)
Trial: 19525834
Drug: Steroid caudal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid caudal epidural injections (CEI) containing 12 mL of xylocaine 2% and 1 mL of betamethasone dipropionate and betamethasone phosphate (2 + 5) mg/dL
Trial: 19525834
Drug: Water for
RxNorm normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water for Injection (WFI) caudal epidural injections containing 12 mL of xylocaine 2% and 8 mL of WFI
Trial: 10382124
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (omeprazole, 20 mg bid, and amoxicillin, 1 gm bid, or clarithromycin, 500 mg tid)
Trial: 10382124
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (omeprazole, 20 mg bid, plus metronidazole, 500 mg bid, and amoxicillin, 1,000 mg bid, or clarithromycin, 500 mg tid)
Trial: 10382124
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (omeprazole, 20 mg bid, plus metronidazole, 500 mg bid, plus tetracycline, 500 mg qid, or doxycycline, 100 mg tid)
Trial: 2789925
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ICS 205-930
Trial: 2789925
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ICS 205-930
Trial: 795183
Drug: Diflucortolone valerate
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucortolone valerate fatty ointment
Trial: 1183219
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide ointment
Trial: 30537098
Drug: Progesterone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (400 mg/day for 7 days)
Trial: 22677752
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of reamberin and cycloferon
Trial: 22433807
Drug: Generally accepted
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generally accepted therapy
Trial: 16855141
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone response to hypoglycemia in SSc and PsA patients
Trial: 16855141
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone response to hypoglycemia in healthy controls
Trial: 15087264
Drug: High procyanidin
RxNorm normalized name: procyanidin A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High procyanidin chocolate (200 mg of flavanols and related procyanidins)
Trial: 15087264
Drug: Low procyanidin
RxNorm normalized name: procyanidin A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low procyanidin chocolate (less than 10 mg of polyphenols)
Trial: 10958263
Drug: New serotonergic-noradrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New serotonergic-noradrenergic antidepressant
Trial: 7956958
Drug: Planned chronic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Planned chronic injection sclerotherapy (at three weekly intervals)
Trial: 7956958
Drug: Demand injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demand injection sclerotherapy (after variceal bleeds only)
Trial: 28956620
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (CBT + sertraline)
Trial: 28582570
Drug: Filorexant 10
RxNorm normalized name: Filorexant
DrugBank: Filorexant (DB12158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filorexant 10 mg
Trial: 21533995
Drug: Levodopa/carbidopa 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa 100 mg three times on day 1
Trial: 21533995
Drug: Levodopa/carbidopa 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa 100 mg with COMT-inhibitor entacapone (EN) on day 2
Trial: 14627174
Drug: Budesonide/formoterol (Symbicort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 mg, two inhalations b.i.d.
Trial: 2859077
Drug: Dexamphetamine sulphate
RxNorm normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamphetamine sulphate tablets 10 mg
Trial: 2859077
Drug: Dexamphetamine sulphate
RxNorm normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamphetamine sulphate tablets 30 mg
Trial: 2859077
Drug: Dexedrine Spansules
RxNorm normalized name: Dextroamphetamine Sulfate 5 MG Oral Capsule, Extended Release [DEXEDRINE SPANSULES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexedrine Spansules 10 mg
Trial: 2859077
Drug: Mazindol 4
RxNorm normalized name: Mazindol
DrugBank: Mazindol (DB00579)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mazindol 4 mg
Trial: 2859077
Drug: Fencamfamin hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fencamfamin (DB01463)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fencamfamin hydrochloride 60 mg
Trial: 27550361
Drug: AZD5847 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5847 at 500 mg twice daily
Trial: 27550361
Drug: AZD5847 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5847 at 500 mg once daily
Trial: 27550361
Drug: AZD5847 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5847 at 1,200 mg once daily
Trial: 27550361
Drug: AZD5847 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5847 at 800 mg twice daily
Trial: 27550361
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of isoniazid, rifampin, ethambutol, and pyrazinamide (standard chemotherapy)
Trial: 24907877
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml 0.5% bupivacaine (Group B)
Trial: 24907877
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml 0.5% levobupivacaine (Group L)
Trial: 24907877
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both groups (Group B and Group L)
Trial: 21962098
Drug: Nasal carbon
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal carbon dioxide (10 mL/s for 10 seconds per nostril)